{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:11:00Z","timestamp":1790878260578,"version":"4.1.0"},"reference-count":31,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019718","name":"Iten-Kohaut-Foundation","doi-asserted-by":"publisher","award":["IA USZF27071"],"award-info":[{"award-number":["IA USZF27071"]}],"id":[{"id":"10.13039\/501100019718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Objectives: We aimed to investigate sex-related differences in patients with advanced melanoma treated with ICI by linking the assessment of inflammatory response in peripheral blood, onset of immune-related adverse events IRAEs during therapy and treatment response in short- and long-term. Methods: For the purpose of this single-center retrospective study metastatic melanoma patients treated with ICI were included. Baseline patient characteristics, blood sample tests and the onset of immune-related adverse events IRAEs were documented based on clinical records. The short-term treatment response was assessed with 18F-2-Fluor-2-desoxy-D-glucose Positron Emission Tomography\/Computed Tomography FDG-PET\/CT scans performed six months after initiation of ICI. The overall survival OS and progression-free survival PFS were used as endpoints to assess the long-term response to immunotherapy. Results: In total, 103 patients with advanced melanoma (mean age 68 \u00b1 13.83 years) were included, 29 women (mean age 60.41 \u00b1 14.57 years) and 74 men (mean age 65.66 \u00b1 13.34 years). The primary tumor was located on a lower extremity in one out of three women and on the head\/neck in one out of three men (p &lt; 0.001). While the superficial spreading (41%) and nodular (36%) melanoma subtypes represented together 77% of the cases in male population, women showed a more heterogenous distribution of melanoma subtypes with the superficial spreading (35%), nodular (23%), acral lentiginous (19%) and mucosal (12%) melanoma subtypes being most frequent in female population (p &lt; 0.001). Most differences between women and men with regards to inflammatory parameters were observed six months after initiation of ICI with a higher median NLR (p = 0.038), lower counts of lymphocytes (p = 0.004) and thrombocytes (p = 0.089) in addition to lower counts of erythrocytes (p &lt; 0.001) and monocytes (p &lt; 0.001) in women towards men. IRAEs were more frequent in women towards men (p = 0.013). Women were more likely to display endocrinological IRAEs, such as thyroiditis being the most frequent adverse event in women. Interestingly IRAEs of the gastrointestinal tract were the most frequent ones in men. Finally, men with advanced melanoma showed a significantly better response to immunotherapy in short- (p = 0.015) and long-term (OS p = 0.015 and PFS p &lt; 0.001) than women. In fact, every fourth man died during the course of the disease, while every second woman did not survive. (p = 0.001). Conclusion: Men with advanced melanoma showed a significantly better response to immunotherapy in short- and long-term than women. Higher immune activation in peripheral blood before and after initiation ICI might be linked to favorable treatment response during and after ICI in favor of men and decoupled from the onset of IRAEs. Given the significantly higher immunotoxicity and worse outcome experienced by women compared to men the use of ICI should be chosen carefully in women with advanced melanoma.<\/jats:p>","DOI":"10.3390\/cancers14205145","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T20:35:55Z","timestamp":1666298155000},"page":"5145","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Sex-Related Differences in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition"],"prefix":"10.3390","volume":"14","author":[{"given":"Ken","family":"Kudura","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Basler","sequence":"additional","affiliation":[{"name":"Institute of Radiooncology, Cantonal Hospital Aarau, 5001 Aarau, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Nussbaumer","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7664-9207","authenticated-orcid":false,"given":"Robert","family":"Foerster","sequence":"additional","affiliation":[{"name":"Institute of Radiooncology, Cantonal Hospital Winterthur, 8400 Winterthur, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Kudura, K., Dimitriou, F., Mihic-Probst, D., Muehlematter, U., Kutzker, T., Basler, L., F\u00f6rster, R., Dummer, R., Mangana, J., and Husmann, L. (2021). Malignancy Rate of Indeterminate Findings on FDG-PET\/CT in Cutaneous Melanoma Patients. Diagnostics, 11.","DOI":"10.3390\/diagnostics11050883"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1089\/jwh.2021.0223","article-title":"Sex Differences in Cutaneous Melanoma: Incidence, Clinicopathological Profile, Survival, and Costs","volume":"31","author":"Buja","year":"2022","journal-title":"J. Women\u2019s Health"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kudura, K., Dimitriou, F., Basler, L., F\u00f6rster, R., Mihic-Probst, D., Kutzker, T., Dummer, R., Mangana, J., Burger, I.A., and Kreissl, M.C. (2021). Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET\/CT in Melanoma Patients. Cancers, 15.","DOI":"10.3390\/cancers13153830"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"adv00136","DOI":"10.2340\/00015555-3491","article-title":"Melanoma Epidemiology and Sun Exposure","volume":"100","author":"Raimondi","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/jamadermatol.2020.0470","article-title":"Evaluation of Sex-Specific Incidence of Melanoma","volume":"156","author":"Olsen","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1158\/1078-0432.CCR-20-4314","article-title":"Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms","volume":"27","author":"Abbott","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12253-018-0466-9","article-title":"Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab","volume":"26","author":"Balatoni","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Wang, S., Cowley, L.A., and Liu, X.-S. (2019). Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy. Molecules, 24.","DOI":"10.3390\/molecules24183214"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1080\/14740338.2021.1939672","article-title":"The Effect of Patient Sex on the Efficacy and Safety of Anticancer Immunotherapy","volume":"20","author":"Pala","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bellenghi, M., Puglisi, R., Pontecorvi, G., De De Feo, A., Car\u00e8, A., and Mattia, G. (2020). Sex and Gender Disparities in Melanoma. Cancers, 12.","DOI":"10.3390\/cancers12071819"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"99336","DOI":"10.18632\/oncotarget.22242","article-title":"The Sexist Behaviour of Immune Checkpoint Inhibitors in Cancer Therapy?","volume":"8","author":"Botticelli","year":"2017","journal-title":"Oncotarget"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer Immunotherapy Efficacy and Patients\u2019 Sex: A Systematic Review and Meta-Analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13293-020-00301-y","article-title":"The impact of sex and gender on immunotherapy outcomes","volume":"11","author":"Klein","year":"2020","journal-title":"Biol. Sex Differ."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex Differences in Immune Responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"van der Kooij, M.K., Dekkers, O.M., Aarts, M.J.B., Berkmortel, F.W.P.J.V.D., Boers-Sonderen, M.J., de Groot, J.W.B., Hospers, G.A.P., Piersma, D., van Rijn, R.S., and Suijkerbuijk, K.P.M. (2021). Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study. Cancers, 13.","DOI":"10.3390\/cancers13184639"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"15413","DOI":"10.18632\/aging.203100","article-title":"Sex-Related Differences in the Efficacy of Immune Checkpoint Inhibitors in Malignancy: A Systematic Review and Meta-Analysis","volume":"13","author":"Lai","year":"2021","journal-title":"Aging"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41467-020-15679-x","article-title":"Sex-Associated Molecular Differences for Cancer Immunotherapy","volume":"11","author":"Ye","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Dimitriou, F., Staeger, R., Ak, M., Maissen, M., Kudura, K., Barysch, M., Levesque, M., Cheng, P., Dummer, R., and Mangana, J. (2021). Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis. Cancers, 13.","DOI":"10.3390\/cancers13122931"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2020.09.001","article-title":"Prospective Evaluation of the Prognostic Value of Immune-Related Adverse Events in Patients with Non-Melanoma Solid Tumour Treated with PD-1\/PD-L1 Inhibitors Alone and in Combination with Radiotherapy","volume":"140","author":"Schweizer","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/CJI.0000000000000392","article-title":"The Prognostic Significance of Baseline Neutrophil-to-Lymphocyte Ratio in Melanoma Patients Receiving Immunotherapy","volume":"45","author":"Li","year":"2022","journal-title":"J. Immunother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2020.03.017","article-title":"Association between Immune-Related Adverse Events and Long-Term Survival Outcomes in Patients Treated with Immune Checkpoint Inhibitors","volume":"132","author":"Maillet","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9029","DOI":"10.1038\/s41598-021-88307-3","article-title":"Association of Blood Biomarkers and Autoimmunity with Immune Related Adverse Events in Patients with Cancer Treated with Immune Checkpoint Inhibitors","volume":"11","author":"Michailidou","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"77404","DOI":"10.18632\/oncotarget.12677","article-title":"Nivolumab for Advanced Melanoma: Pretreatment Prognostic Factors and Early Outcome Markers during Therapy","volume":"7","author":"Nakamura","year":"2016","journal-title":"Oncotarget"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/jjco\/hyy201","article-title":"Correlation between Blood Cell Count and Outcome of Melanoma Patients Treated with Anti-PD-1 Antibodies","volume":"49","author":"Nakamura","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5582\/ddt.2020.03043","article-title":"Increase of Lymphocytes and Eosinophils, and Decrease of Neutrophils at an Early Stage of Anti-PD-1 Antibody Treatment Is a Favorable Sign for Advanced Malignant Melanoma","volume":"14","author":"Ohashi","year":"2020","journal-title":"Drug Discov. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1634\/theoncologist.2018-0563","article-title":"Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors","volume":"24","author":"Pavan","year":"2019","journal-title":"Oncologist"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1158\/1078-0432.CCR-20-0020","article-title":"Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition","volume":"26","author":"Basler","year":"2020","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.abd.2020.08.022","article-title":"Cutaneous melanoma: A retrospective study of 18 years. Are there gender differences?","volume":"96","author":"Souza","year":"2021","journal-title":"An. Bras. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/CJI.0000000000000403","article-title":"Different Response to Immunotherapy According to Melanoma Histologic Subtype","volume":"45","author":"Pala","year":"2022","journal-title":"J. Immunother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ijom.2019.11.001","article-title":"Sinonasal Melanoma: A Systematic Review of the Prognostic Factors","volume":"49","author":"Pontes","year":"2020","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1016\/j.jormas.2022.02.002","article-title":"Oral Mucosal Melanoma\u2014A Systematic Review","volume":"5","author":"Thuaire","year":"2022","journal-title":"J. Stomatol. Oral Maxillofac. Surg."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/20\/5145\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:58:14Z","timestamp":1760144294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/20\/5145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":31,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["cancers14205145"],"URL":"https:\/\/doi.org\/10.3390\/cancers14205145","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]}}}